Anand A. Date
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anand A. Date has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Alison M. Rue
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publication- Charles F. Gilks
School of Public Health, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD 4000, Australia
1 shared publication Gustavo H. Dayan
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publicationJosh Rowland
Nebraska Public Health Laboratory, University of Nebraska Medical Center , Omaha, Nebraska
1 shared publicationJulie Klahn
University of Nebraska at Kearney
1 shared publicationLeAnn Obrecht
University of Nebraska at Kearney , Kearney
1 shared publication
Latest Publications
- 23 October 2009
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 88 (4) , 253-259
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV
To measure progress in implementing co-trimoxazole prophylaxis (CTXp) (trimethoprim plus sulfamethoxazole) and isoniazid preventive therapy (IPT) policy recommendations, identify barriers to the development of national policies and pinpoint challenges to implementation. In 2007 we conducted by e-mail a cross-sectional survey of World Health Organization (WHO) HIV/AIDS programme officers in 69 selected countries having a high burden of infection with HIV or HIV-associated tuberculosis (TB). The specially-designed, self-administered questionnaire contained items covering national policies for CTXp and IPT in people living with HIV, current level of implementation and barriers to developing or implementing these policies. The 41 (59%) respondent countries, representing all WHO regions, comprised 85% of the global burden of HIV-associated TB and 82% of the global burden of HIV infection. Thirty-eight countries (93%) had an established national policy for CTXp, but only 66% of them (25/38) had achieved nationwide implementation. For IPT, 21 of 41 countries (51%) had a national policy but only 28% of them (6/21) had achieved nationwide implementation. Despite significant progress in the development of CTXp policy, the limited availability of co-trimoxazole for this indication and inadequate systems to manage drug supply impeded nationwide implementation. Inadequate intensified tuberculosis case-finding and concerns regarding isoniazid resistance were challenges to the development and implementation of national IPT policies. Despite progress in implementing WHO-recommended CTXp and IPT policies, these interventions remain underused. Urgent steps are required to facilitate the development and implementation of these policies.
- 23 October 2009
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 88 (4) , 253-259
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV
To measure progress in implementing co-trimoxazole prophylaxis (CTXp) (trimethoprim plus sulfamethoxazole) and isoniazid preventive therapy (IPT) policy recommendations, identify barriers to the development of national policies and pinpoint challenges to implementation. In 2007 we conducted by e-mail a cross-sectional survey of World Health Organization (WHO) HIV/AIDS programme officers in 69 selected countries having a high burden of infection with HIV or HIV-associated tuberculosis (TB). The specially-designed, self-administered questionnaire contained items covering national policies for CTXp and IPT in people living with HIV, current level of implementation and barriers to developing or implementing these policies. The 41 (59%) respondent countries, representing all WHO regions, comprised 85% of the global burden of HIV-associated TB and 82% of the global burden of HIV infection. Thirty-eight countries (93%) had an established national policy for CTXp, but only 66% of them (25/38) had achieved nationwide implementation. For IPT, 21 of 41 countries (51%) had a national policy but only 28% of them (6/21) had achieved nationwide implementation. Despite significant progress in the development of CTXp policy, the limited availability of co-trimoxazole for this indication and inadequate systems to manage drug supply impeded nationwide implementation. Inadequate intensified tuberculosis case-finding and concerns regarding isoniazid resistance were challenges to the development and implementation of national IPT policies. Despite progress in implementing WHO-recommended CTXp and IPT policies, these interventions remain underused. Urgent steps are required to facilitate the development and implementation of these policies.
- Open Access
- 15 June 2008
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 197 (12) , 1662-1668
Long‐Term Persistence of Mumps Antibody after Receipt of 2 Measles‐Mumps‐Rubella (MMR) Vaccinations and Antibody Response after a Third MMR Vaccination among a University Population
Background. High attack rates among vaccinated young adults reported during the 2006 mumps outbreak in the United States heightened concerns regardin
- 15 June 2008
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 197 (12) , 1662-1668
Open AccessLong‐Term Persistence of Mumps Antibody after Receipt of 2 Measles‐Mumps‐Rubella (MMR) Vaccinations and Antibody Response after a Third MMR Vaccination among a University Population
Background. High attack rates among vaccinated young adults reported during the 2006 mumps outbreak in the United States heightened concerns regardin